Biocon, Quark Win Pioneering Indian Nod For RNAi Eye Therapy Trial
This article was originally published in PharmAsia News
Executive Summary
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.